Recruiting

Segmentectomy for Solid-dominant Invasive Lung Cancer 2-3cm

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Segmentectomy

Procedure
Who is being recruted

Adenocarcinoma of Lung+7

+ Adenocarcinoma

+ Carcinoma

From 18 to 80 Years
+15 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 3
Interventional
Study Start: July 2024
See protocol details

Summary

Principal SponsorFudan University
Study ContactFangqiu Fu, M.D.
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: July 1, 2024

Actual date on which the first participant was enrolled.

This clinical trial explores the effectiveness of a surgical procedure called segmentectomy for treating a specific type of lung cancer. It focuses on patients with solid-dominant invasive lung cancer, where the tumor size is between 2 to 3 centimeters. The aim is to assess how well this surgery can prevent cancer from returning over five years and to evaluate the lung function of patients after the surgery. By understanding these outcomes, the study hopes to improve treatment options for individuals dealing with this form of lung cancer and provide insights into the benefits of segmentectomy. Participants in this trial will undergo segmentectomy, which involves removing a portion of the lung where the cancer is located. Researchers will monitor patients to determine if they remain free of cancer over a five-year period. They will also perform tests to check how well the lungs function after the surgery. The study does not specify any risks or benefits, but it aims to gather valuable data on the effectiveness and impact of segmentectomy on lung cancer patients. This information could potentially enhance treatment strategies and patient outcomes in the future.

Official TitleSegmentectomy for Solid-dominant GGO-featured Invasive Lung Cancer With Size of 2-3cm: a Single-arm, Multi-center, Phase III Trial
NCT06634966
Principal SponsorFudan University
Study ContactFangqiu Fu, M.D.
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

277 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 80 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Adenocarcinoma of LungAdenocarcinomaCarcinomaLung NeoplasmsNeoplasmsNeoplasms by Histologic TypeNeoplasms by SiteNeoplasms, Glandular and EpithelialRespiratory Tract NeoplasmsThoracic Neoplasms

Criteria

10 inclusion criteria required to participate
Patients who sign the informed consent form and are willing to complete the study according to the plan;
Aged from 18 to 80 years old;
ECOG equals 0 or 1;
Not receiving lung cancer surgery before;
Show More Criteria
5 exclusion criteria prevent from participating
CTR is not 0.5-1, or size is not 2-3cm;
Tumors could not be completely resected assed by surgeons;
Not lung adenocarcinoma diagnosed cytologically or pathologically;
Receiving lung cancer surgery before;
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Segmentectomy is performed for solid-dominant invasive lung cancer with size of 2-3cm.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Fudan University Shanghai Cancer Center

Shanghai, ChinaOpen Fudan University Shanghai Cancer Center in Google Maps
Recruiting
One Study Center